Results 111 to 120 of about 119,167 (297)

Semaglutide normalizes increased cardiomyocyte calcium transients in a rat model of high fat diet‐induced obesity

ESC Heart Failure, Volume 12, Issue 2, Page 1386-1397, April 2025.
Sequeira et al. reveal how the glucagon‐like peptide‐1 receptor agonist (GLP‐1‐RA) semaglutide restores cardiomyocyte function in rats subjected to a high‐fat/high‐fructose diet (HFD). Employing fluorescence‐ and patch‐clamp technology in isolated cardiac myocytes, they demonstrate that semaglutide reverses HFD‐induced activation of L‐type calcium ...
Vasco Sequeira, Julia Theisen, Katharina J. Ermer, Marie Oertel, Anton Xu, David Weissman, Katharina Ecker, Jan Dudek, Martin Fassnacht, Alexander Nickel, Michael Kohlhaas, Christoph Maack, Ulrich Dischinger   +12 more
wiley   +1 more source

Enteroendocrine-derived glucagon-like peptide-2 controls intestinal amino acid transport

Molecular Metabolism, 2017
Objective: Glucagon-like peptide-2 (GLP-2) is co-secreted with GLP-1 from gut endocrine cells, and both peptides act as growth factors to expand the surface area of the mucosal epithelium.
Jennifer Lee, Jacqueline Koehler, Bernardo Yusta, Jasmine Bahrami, Dianne Matthews, Mahroukh Rafii, Paul B. Pencharz, Daniel J. Drucker   +7 more
doaj   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Mapping the Global Clinical Landscape of Pharmacological Therapies for Heart Failure With Preserved Ejection Fraction: An Analysis Based on ClinicalTrials.gov (2003–2025)

iMetaMed, EarlyView.
This study analyzed 236 heart failure with preserved ejection fraction (HFpEF) pharmacological trials registered on ClinicalTrials.gov from 2003 to 2025, revealing a post‐2016 surge (76.3%), U.S. dominance (58.5%), and prominence of SGLT2 inhibitors/novel therapies (each 13.1%).
Yucheng Hou, Jingwei Zhao, Yuqian Tang, Tan Liu, Zhiao Zhang, Ziheng Wang, Han Shen   +6 more
wiley   +1 more source

Probiotics‐derived postbiotics improve host metabolic syndrome by activating the adipocyte thermogenic signaling pathway in high‐fat diet‐fed mice

iMetaOmics, EarlyView.
This schematic illustrates how probiotics‐derived postbiotics (PLBK®1–5) combat high‐fat diet‐induced obesity. Postbiotics remodel gut microbiota, boosting beneficial metabolites. These metabolites activate adipocyte thermogenesis (Ucp1/AMPK pathway), resulting in reduced body weight, improved insulin sensitivity, and alleviated hepatic steatosis in ...
Ye Tian, Liujing Huang, Yifan Liu, Xudong Mai, Yanbo Cheng, Bingdong Liu, Yixin Chen, Liwei Xie   +7 more
wiley   +1 more source

Diffuse Podocytopathy Associated With Semaglutide

Annals of Internal Medicine: Clinical Cases
We present 3 cases of biopsy-proven minimal change disease occurring in close temporal association with semaglutide (glucagon-like peptide 1 receptor agonists) exposure.
Rose Mary Attieh, Grant Kirby, Yang Yihe, Serena Bagnasco, Andrew A. Moses, Mahmoud Abdelaziz, Rimda Wanchoo, Samir Gautam, Astrid Weins, Kenar D. Jhaveri   +9 more
doaj   +1 more source

Metabolic Signatures and Diagnostic Prediction Models for Coronary Artery Disease and Type 2 Diabetes Mellitus: Insights From an Exploratory Study

iNew Medicine, EarlyView.
Metabolomic & lipidomic analysis reveals metabolic overlap between CAD & T2DM, highlighting 7 key metabolites as potential biomarkers. A predictive model based on these achieves high accuracy, potentially advancing precision medicine & metabolic insights.
Zhihua Wang, Meiming Su, Ying Li, Yapei Li, Shuo Chen, Ting Peng, Hans Strijdom, Jiangang Wang, Jianping Weng, Suowen Xu   +9 more
wiley   +1 more source

The glucagon-like Peptide-2

, 2011
Multiple peptide hormones produced within the gastrointestinal system act also in the central nervous system and aid in the regulation of energy homeostasis and metabolism. The list of these peptides is progressively increasing and includes glucagon-like peptide 2 (GLP-2) as an anorexigenic factor.
openaire   +2 more sources

Insulin Resistance: An Update on Biochemical and Pathophysiological Mechanisms and Impact on Various Diseases

iNew Medicine, EarlyView.
ABSTRACT Insulin resistance is the biological phenomenon in which the human body's normal response to the metabolic hormone insulin is compromised. Insulin is a regulator of most of the essential metabolic steps in the body that control energy homoeostasis, so dysregulation leads to multiple diverse human diseases including, most prominently, Type 2 ...
Peter J. Little, Stefan Offermanns, Haaglim Cho, Zhiping Liu, Pinglian Yang, Qiaozhu Su, Henry Wade, Wah Yang, Danielle Kamato, Neale Cohen, Alex Bobik, Iqra Ilyas, Suowen Xu   +12 more
wiley   +1 more source

A narrative review of glucagon-like peptide-1 receptor agonists prior to deep sedation or general anesthesia

Journal of Anesthesia, Analgesia and Critical Care
Glucagon-like peptide-1 receptor agonists are a class of drugs that mimic a natural incretin hormone released by the intestine after meals, and they are well-suited for treating type 2 diabetes.
Luigi Vetrugno, Cristian Deana, Andrea Da Porto, Enrico Boero, Valentina Bellini, Daniele Guerino Biasucci, Elena Giovanna Bignami   +6 more
doaj   +1 more source